» Articles » PMID: 17138806

Population Pharmacokinetics in Geriatric Psychiatry

Overview
Publisher Elsevier
Specialty Geriatrics
Date 2006 Dec 2
PMID 17138806
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Although geriatric patients are the major recipients of drugs, most research during drug development is conducted in healthy younger adults. Safe and effective drug therapy in the elderly requires an understanding of both drug disposition and response in older individuals. One of the major issues in studying the elderly relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics can be used to model drug concentrations from a large population of sparsely sampled individuals. Population pharmacokinetics characterizes both the interindividual (between-subject) and intraindividual (within-subject) variability, and can identify factors that contribute to pharmacokinetic and pharmacodynamic variability. Population pharmacokinetics can be used to aid in designing large clinical trials by simulating virtual data based on the study design. It can also be used to assess consistency of drug exposure and evaluate its effect on clinical outcome. This article reviews the methods used in pharmacokinetic modeling, as well as providing examples of population pharmacokinetic modeling, highlighting its application to geriatric psychiatry.

Citing Articles

A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.

Albanell-Fernandez M, Rodriguez-Reyes M, Bastida C, Soy D Clin Pharmacokinet. 2025; 64(1):1-25.

PMID: 39821208 PMC: 11762427. DOI: 10.1007/s40262-024-01459-z.


Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations.

Albanell-Fernandez M Clin Pharmacokinet. 2024; 64(1):27-52.

PMID: 39707078 PMC: 11762474. DOI: 10.1007/s40262-024-01461-5.


What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.

Xiao T, Wang Z, Li G, Huang S, Zhu X, Liu S Drug Des Devel Ther. 2021; 15:3411-3423.

PMID: 34376974 PMC: 8349538. DOI: 10.2147/DDDT.S316110.


Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Yoshida K, Bies R, Suzuki T, Remington G, Pollock B, Mizuno Y Schizophr Res. 2014; 153(1-3):184-8.

PMID: 24491908 PMC: 3960457. DOI: 10.1016/j.schres.2014.01.017.


Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.

Flint A, Meyers B, Rothschild A, Whyte E, Mulsant B, Rudorfer M BMC Psychiatry. 2013; 13:38.

PMID: 23351522 PMC: 3584803. DOI: 10.1186/1471-244X-13-38.